Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors

Sánchez-Gastaldo, Amparo; Gonzalez-Exposito, Reyes; Garcia-Carbonero, Rocío

doi:10.1007/s11523-016-0419-8

Cited by 4 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a variety of cancer types, VEGFR3 is associated with tumor lymphangiogenesis, lymph node invasion and metastasis ( 76 ). Currently, anti-angiogenic therapies targeting VEGF/VEGFRs signaling pathway include anti-VEGF antibodies (Bevacizumab) ( 77 ), anti-VEGFR2 antibodies (ramucirumab) ( 78 ), and TKIs ( 14 ). Both bevacizumab and ramucirumab have been approved by FDA for use in therapy of a series of malignancies.…”

Section: Which Rtk Is the Key Target?mentioning

confidence: 99%

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?

2020

View full text Add to dashboard Cite

Recent clinical trials have shown several multi-target tyrosine kinase inhibitors (TKIs) to be effective in the treatment of osteosarcoma. However, these TKIs have a number of targets, and it is yet unclear which of these targets has a key role in osteosarcoma treatment. In this review, we first summarize the TKIs that were studied in clinical trials registered on ClinicalTrials.gov. Further, we compare and discuss the targets of these TKIs. We found that TKIs with promising therapeutic effect for osteosarcoma include apatinib, cabozantinib, lenvatinib, regorafenib, and sorafenib. The key targets for osteosarcoma treatment may include VEGFRs and RET. The receptor tyrosine kinases (RTKs) MET, IGF-1R, AXL, PDGFRs, KIT, and FGFRs might be relevant but unimportant targets for osteosarcoma treatment. Inhibition of one type of RTK for the treatment of osteosarcoma is not effective. It is necessary to inhibit several relevant RTKs simultaneously to achieve a breakthrough in osteosarcoma treatment. This review provides comprehensive information on TKI targets relevant in osteosarcoma treatment, and it will be useful for further research in this field.

show abstract

Section: Which Rtk Is the Key Target?mentioning

confidence: 99%

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?

2020

View full text Add to dashboard Cite

show abstract

“…Ramucirumab effectively prevents VEGF ligands from binding and activating the receptor by binding to both soluble and cell surface VEGFR-2. (Sanchez-Gastaldo et al, 2016). Aflibercept, as a decoy receptor, targets VEGF-A, VEGF-B, and PLGF to inhibit angiogenesis.…”

Section: Open Access Edited Bymentioning

confidence: 99%

Aortic dissection induced by vascular endothelial growth factor inhibitors

et al. 2023

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF) contributes to angiogenesis and vasculogenesis. The occurrence and progression of tumors are accompanied by angiogenesis. Vascular endothelial growth factor inhibitors (VEGFI) have been used in anti-tumor treatment. However, aortic dissection (AD) is one of the VEGFI-associated adverse reactions with cute onset, rapid progression, and high case fatality rate. We collected case reports of VEGFI related to aortic dissection in PubMed and CNKI (China National Knowledge Infrastructure) from inception to 28 April 2022. Seventeen case reports were selected. The medication included sunitinib, sorafenib, pazopanib, axitinib, apatinib, anlotinib, bevacizumab, and ramucirumab. This review discusses the pathology, risk factors, diagnosis, and treatment of AD. Vascular endothelial growth factor inhibitors are related to aortic dissection. Although current literature lacks clear statistical evidence on the population, we offer points to encourage further confirmation of the best methods of care for these patients.

show abstract

“…Ramucirumab is a human monoclonal antibody against the extracellular domain of VEGFR2, interfering with VEGF-A binding and further angiogenic signaling. Its use combined with FOLFOX or FOLFIRI has also shown promising results for the treatment of patients with metastatic CRC [320–322]. …”

Section: Colorectal Cancer Treatments and Biomarkersmentioning

confidence: 99%

Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs

Lizarbe

Calle-Espinosa

Fernández-Lizarbe

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Colorectal cancer is the third most common form of cancer in developed countries and, despite the improvements achieved in its treatment options, remains as one of the main causes of cancer-related death. In this review, we first focus on colorectal carcinogenesis and on the genetic and epigenetic alterations involved. In addition, noncoding RNAs have been shown to be important regulators of gene expression. We present a general overview of what is known about these molecules and their role and dysregulation in cancer, with a special focus on the biogenesis, characteristics, and function of microRNAs. These molecules are important regulators of carcinogenesis, progression, invasion, angiogenesis, and metastases in cancer, including colorectal cancer. For this reason, miRNAs can be used as potential biomarkers for diagnosis, prognosis, and efficacy of chemotherapeutic treatments, or even as therapeutic agents, or as targets by themselves. Thus, this review highlights the importance of miRNAs in the development, progression, diagnosis, and therapy of colorectal cancer and summarizes current therapeutic approaches for the treatment of colorectal cancer.

show abstract

Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors

Cited by 4 publications

References 31 publications

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?

Aortic dissection induced by vascular endothelial growth factor inhibitors

Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs

Contact Info

Product

Resources

About